Introducing a new method for practical brain monitoring
CERENION C-TREND® offers the first truly objective and practical method to obtain reliable information on the condition and function of the brain. The clinically validated measure can be integrated into EEG-measurement devices and patient monitors as a software feature.
CERENION C-TREND® is a CE-marked medical-grade software solution that works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The result is a simple index that measures the condition and function of the brain on a scale from 0 to 100.
The technology has the potential of improving both the quality and the cost of intensive care.
What is C-Trend?
C-Trend™ technology is not available in the US.
C-Trend® software utilizes artificial intelligence to process the complex EEG signal into one simple score, C-Trend® Index. The index describes the EEG slow-wave activity (<1 Hz), a neurophysiological feature highly important for healthy brain function, as a single parameter ranging 0 to 100 in values.
In addition to C-Trend Index, C-Trend software provides calculation of three conventional parameters: Burst Suppression Ratio (BSR), Amplitude-Integrated EEG (aEEG), and Alpha-Delta Ratio (ADR). This set of parameters allows C-Trend to be used in a wide variety of conditions in intensive care including:
-Hypoxic ischemic encephalopathy after cardiac arrest -Treatment of status epilepticus with deep anesthesia -Non-convulsive status epilepticus -Delayed cerebral ischemia after subarachnoid hemorrhage
Scientific & Clinical validation
We have our roots in academic research and understand the importance of extensive scientific validation of any new technology. We are located at the heart of the internationally recognized Oulu Health ecosystem in Finland, and have formed close collaboration ties with the University of Oulu and the Oulu University Hospital. Through this work we continue to innovate and test our technology, and also invite others to join in.
We place great value in publishing our findings on high-quality scientific forums, and also wish to help others test out and build on our work. As a part of this, we are engaged in running clinical multisite studies.
"There are currently no reliable methods for assessing brain function in the early stages of recovery from hypoxic, ischemic, or traumatic insults that might inform neurologic prognosis and therapy. Slow electroencephalographic waves induced by general anesthetics might provide a neurophysiologic signature of healthy brain function."
Hugh C. Hemmings, M.D., Ph.D., Handling Editor, Anesthesiology in regards to our scientific publication in the journal
"Outstanding example of research."
Professor Esa Mervaala, Council Chair, Vaajasalo Foundation in regards to our scientific publication recognized at NCCN & KES 2017
"This invention will ease the day-to-day work at intensive care units"
Associate Chief Physician of Intensive Care, Dr. Jouko Laurila in newspapers Kaleva, Aamulehti, Turun Sanomat, Lapin Kansa, Forssan Lehti, Ilkka and Pohjalainen
"The technology Cerenion is developing has great potential in helping EEG specialists in faster and more accurate interpretation of EEG"
Chief Physician of Clinical Neurophysiology, Dr. Mika Kallio
Cerenion Oy has received support from the European Regional Development Fund of the European Union.
Cerenion Oy Elektroniikkatie 3 90590 Oulu FINLAND
Cerenion Oy Firdonkatu 2 T 63 00520 Helsinki FINLAND